SG Americas Securities LLC Makes New Investment in HilleVax, Inc. (NASDAQ:HLVX)

SG Americas Securities LLC purchased a new position in shares of HilleVax, Inc. (NASDAQ:HLVX) during the fourth quarter, Holdings Channel.com reports. The fund purchased 8,686 shares of the company’s stock, valued at approximately $139,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of HLVX. JPMorgan Chase & Co. purchased a new stake in HilleVax during the second quarter worth about $76,000. Rhumbline Advisers acquired a new position in shares of HilleVax during the second quarter worth about $187,000. Northern Trust Corp acquired a new position in shares of HilleVax during the second quarter worth about $1,145,000. American International Group Inc. acquired a new position in shares of HilleVax during the second quarter worth about $66,000. Finally, Millennium Management LLC acquired a new position in shares of HilleVax during the second quarter worth about $185,000. 86.42% of the stock is currently owned by hedge funds and other institutional investors.

HilleVax Stock Performance

Shares of HilleVax stock opened at $13.01 on Wednesday. HilleVax, Inc. has a one year low of $9.94 and a one year high of $20.22. The company has a market cap of $646.60 million, a PE ratio of -4.28 and a beta of 0.65. The company has a debt-to-equity ratio of 0.10, a quick ratio of 10.62 and a current ratio of 10.62. The business has a 50-day simple moving average of $16.20 and a 200-day simple moving average of $14.65.

HilleVax (NASDAQ:HLVX) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.02. On average, equities research analysts forecast that HilleVax, Inc. will post -3.22 EPS for the current fiscal year.

Insider Activity at HilleVax

In related news, CFO Shane Maltbie sold 3,576 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $14.93, for a total value of $53,389.68. Following the completion of the transaction, the chief financial officer now directly owns 40,656 shares of the company’s stock, valued at $606,994.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Shane Maltbie sold 3,576 shares of the company’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $14.93, for a total value of $53,389.68. Following the completion of the transaction, the chief financial officer now directly owns 40,656 shares of the company’s stock, valued at $606,994.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Aditya Kohli sold 6,000 shares of the business’s stock in a transaction that occurred on Friday, April 5th. The shares were sold at an average price of $14.44, for a total value of $86,640.00. Following the completion of the sale, the director now owns 789,776 shares of the company’s stock, valued at approximately $11,404,365.44. The disclosure for this sale can be found here. Insiders sold 78,039 shares of company stock valued at $986,464,242 over the last three months. 29.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $28.00 price objective on shares of HilleVax in a research report on Thursday, March 21st.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.